% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Galldiks:288867,
author = {N. Galldiks and T. J. Kaufmann and P. Vollmuth and P.
Lohmann and M. Smits and M. C. Veronesi and K.-J. Langen and
R. Rudá and N. L. Albert$^*$ and E. Hattingen and I. Law
and M. Hutterer and R. Soffietti and M. A. Vogelbaum and P.
Y. Wen and M. Weller and J.-C. Tonn$^*$},
title = {{C}hallenges, {L}imitations and {P}itfalls of {PET} and
{A}dvanced {MRI} in {P}atients with {B}rain {T}umors - {A}
{R}eport of the {PET}/{RANO} {G}roup.},
journal = {Neuro-Oncology},
volume = {26},
number = {7},
issn = {1522-8517},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DKFZ-2024-00514},
pages = {1181-1194},
year = {2024},
note = {2024 Jul 5;26(7):1181-1194},
abstract = {Brain tumor diagnostics have significantly evolved with the
use of PET and advanced MRI techniques. In addition to
anatomical MRI, these modalities may provide valuable
information for several clinical applications such as
differential diagnosis, delineation of tumor extent,
prognostication, differentiation between tumor relapse and
treatment-related changes, and the evaluation of response to
anticancer therapy. In particular, joint recommendations of
the RANO group, the EANO, and major European and American
Nuclear Medicine societies highlighted that the additional
clinical value of radiolabeled amino acids compared to
anatomical MRI alone is outstanding and that its widespread
clinical use should be supported. For advanced MRI and its
steadily increasing use in clinical practice, the
Standardization Subcommittee of the Jumpstarting Brain Tumor
Drug Development Coalition provided more recently an updated
acquisition protocol for the widely used dynamic
susceptibility contrast perfusion MRI. Besides amino acid
PET and perfusion MRI, other PET tracers and advanced MRI
techniques (e.g., MR spectroscopy) are of considerable
clinical interest and are increasingly integrated into
everyday clinical practice. Nevertheless, these modalities
have shortcomings which should be considered in clinical
routine. This comprehensive review provides an overview of
potential challenges, limitations and pitfalls associated
with PET imaging and advanced MRI techniques in patients
with gliomas or brain metastases. Despite these issues, PET
imaging and advanced MRI techniques continue to play an
indispensable role in brain tumor management. Acknowledging
and mitigating these challenges through interdisciplinary
collaboration, standardized protocols, and continuous
innovation will further enhance the utility of these
modalities in guiding optimal patient care.},
keywords = {CEST (Other) / MR spectroscopy (Other) / amino acid PET
(Other) / diffusion-weighted imaging (Other) /
perfusion-weighted imaging (Other)},
cin = {MU01},
ddc = {610},
cid = {I:(DE-He78)MU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38466087},
doi = {10.1093/neuonc/noae049},
url = {https://inrepo02.dkfz.de/record/288867},
}